EuroPharma Today

Austerity Holds Back VC Investing in European Biotech Companies in 2011

Funding for private biotech companies in Europe declines 17% during 2011, while funding for public biotech companies falls 50%, although 2012 starts strongly.

U.K. To Leverage NHS Data As Part Of Broader Stimulus Package, But Details Still Sketchy

Industry welcomed the initiatives, which included making National Health Service clinical data more widely available and strengthening NICE's role.

Grunenthal CEO Claims German Reimbursement Hurdle Is Fair, As Pain Drug Palexia Rolls Out Across Europe

German reimbursement authority’s strong emphasis on drugs’ added benefit is logical, opines Grunenthal CEO Harald Stock. And all health care systems will eventually move the same way.

AZ’s Brillinta Is First Drug To Clear AMNOG Assessment, While Merck’s Victrelis Limps Forward

Lack of consistent approach in IQWiG/G-BA AMNOG-based decisions leaves industry confused about new reimbursement route.

Euro Crisis Hits Investor Risk Appetite, But Opportunities Remain

There are good-value opportunities in Europe for VCs with money to invest, but those seeking new funds face an unprecedentedly tough challenge that’s compounded by euro uncertainty.

The End of The Euro: What Might It Mean For Pharma?

Companies struggle on how even to begin assessing impact of a possible Euro break-up.

The End of The Euro: What Might It Mean For Pharma?

Companies struggle on how even to begin assessing impact of a possible Euro break-up.

French Pharma Industry Pays The Price For Country’s Financial Woes

 

In an effort to shore up its credit rating, the French government has turned the financial screw on pharmaceutical manufacturers.

Rx Class Action Suits May Come To France In Response To Mediator Scandal

A bill in the French upper house of parliament, the Senate, aimed at averting conflicts of interest in the pharmaceutical sector now has a section that could in fact encourage conflict by creating potentially painful class action cases against firms.

Invitation to Innovative Drug R&D in Russia Forum

Adam Smith Conferences’ Innovative Drug R&D in Russia Forum will take place on 21-22 November in Moscow.

This years’ Forum is set to become the one industry gathering that you cannot afford to miss!